FDA approves first cell therapy for solid tumors

The solid tumor therapy, Amtagvi, costs $515,000 and will be sold by California biotech Iovance.

February 20, 2024 Check out STAT+

Sponsored By

Julio C. Valencia,/NCI Center for Cancer Research STAT+ | In 'major milestone,' FDA approves first cell therapy for solid tumors A tumor infiltrating lymphocyte therapy by Iovance helped a significant number of advanced melanoma patients. By Angus Chen STAT+ | Leading MD Anderson oncologist disputes junior scientist's claims in lawsuit over research credit Padmanee Sharma, one of MD Anderson's most influential researchers, provided her own account of events in a contentious case. By Angus Chen 'All of Us' reports half of the genomes it has sequenced are from non-Europeans The data release this week includes the whole genome sequences of nearly 250,000 participants — half of whom are of non-European ancestry. By Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser